Mohsen Mohammad Rahimi
1 
, Elham Jahantabi
2, Behzad Lotfi
3, Mehdi Forouzesh
4, Rohollah Valizadeh
5 , Saman Farshid
6* 1 Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Urology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
4 Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
5 Student Research Committee, Department of Epidemiology, School of Public Health, Tehran, Iran University of Medical Sciences, Tehran, Iran
6 Department of Urology and Nephrology, Urmia University of Medical Sciences, Urmia, Iran
Abstract
Remdesivir initially was intravenously administrated to treat the Ebola disease however right now it has been administered to treat COVID-19 in some countries. However it is necessary to find the exact effect of remdesivir in patients with COVID-19. Remdesivir solution is administered with a cyclodextrin carrier that filters solely by the glomeruli; thereby patients with abnormal renal function cannot eliminate it quickly; therefore, remdesivir can lead to renal failure or liver dysfunction during therapeutic process of COVID-19. Assessment of renal function in patients with COVID-19 who have acute kidney injury (AKI) or end-stage renal disease is fundamental.
Implication for health policy/practice/research/medical education: In the patients taking remdesivir, liver and kidney function tests should be monitored daily, and remdesivir should be held in patients with increased liver enzymes or kidney function impairment.
Please cite this paper as: Rahimi MM, Jahantabi E, Lotfi B, Forouzesh M, Valizadeh R, Farshid S. Renal and liver injury following the treatment of COVID-19 by remdesivir. J Nephropathol. 2021;10(2):e10. DOI: 10.34172/jnp.2021.10.